Publication | Open Access

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Health SciencesMedicineConcurrent ChemoradiationCancer TreatmentOncologyRadiation OncologyCancer ResearchCancer GrowthRadiologyUnresectable Egfr-mutant Nsclc